Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2023 Jan 17;4(1):100904.
doi: 10.1016/j.xcrm.2022.100904.

Size matters in non-canonical inflammasome activation and cell-mediated immunity

Adam M Weiss  1 , Aaron P Esser-Kahn  2
Affiliations
Comment

Size matters in non-canonical inflammasome activation and cell-mediated immunity

Adam M Weiss et al. Cell Rep Med. .

Abstract

Particulate adjuvants are key components of many approved vaccines, but their mechanism of adjuvanticity is debated. Muñoz-Wolf et al.1 find that 50-nm particles maximize cell-mediated immune responses by activating the caspase-11 inflammasome, providing mechanistic insight to particulate adjuvant technologies.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Figures

Figure 1
Figure 1
Model of Caspase-11 mediated cellular immunity generated by polymeric nanoparticles 50-nm nanoparticles induced ROS production, while larger particles did not. ROS production facilitated caspase-11 inflammasome activation, resulting in pyroptosis and secretion of IL-1 cytokines. IL-1α/β mediated a Th1-biased, antigen-specific CD4+ T cell response, while IL-18 mediated an antigen-specific CD8+ T cell response. Created with BioRender.com.
See this image and copyright information in PMC

Comment on

  • Non-canonical inflammasome activation mediates the adjuvanticity of nanoparticles.
    Muñoz-Wolf N, Ward RW, Hearnden CH, Sharp FA, Geoghegan J, O'Grady K, McEntee CP, Shanahan KA, Guy C, Bowie AG, Campbell M, Roces CB, Anderluzzi G, Webb C, Perrie Y, Creagh E, Lavelle EC. Muñoz-Wolf N, et al. Cell Rep Med. 2023 Jan 17;4(1):100899. doi: 10.1016/j.xcrm.2022.100899. Cell Rep Med. 2023. PMID: 36652908 Free PMC article.

References

    1. Munoz-Wolf N., Ward R.W., Hearnden C.H., Sharp F.A., Geoghegan J., O'Grady K., McEntee C.P., Shanahan K.A., Guy C., Bowie A.G., et al. Non-canonical inflammasome activation mediates the adjuvanticity of nanoparticles. Cell Rep. Med. 2022;4 - PMC - PubMed
    1. Pulendran B., S Arunachalam P., O'Hagan D.T. Emerging concepts in the science of vaccine adjuvants. Nat. Rev. Drug Discov. 2021;20:454–475. doi: 10.1038/s41573-021-00163-y. - DOI - PMC - PubMed
    1. Bachmann M.F., Jennings G.T. Vaccine delivery: A matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 2010;10:787–796. doi: 10.1038/nri2868. - DOI - PubMed
    1. Gavin A.L., Hoebe K., Duong B., Ota T., Martin C., Beutler B., Nemazee D. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science. 2006;314:1936–1938. doi: 10.1126/science.1135299. - DOI - PMC - PubMed
    1. Deets K.A., Vance R.E. Inflammasomes and adaptive immune responses. Nat. Immunol. 2021;22:412–422. doi: 10.1038/s41590-021-00869-6. - DOI - PubMed

Publication types

MeSH terms

Substances